Searchable abstracts of presentations at key conferences in obesity
Previous issue | Volume 3 | OU2021 | Next issue

Obesity Update 2021

Online, United Kingdom
30 Jun 2021 - 01 Jul 2021

Card image cap
Registration for Obesity Update 2021 is now open! Join us virtually over two half days on Wednesday 30 June and Thursday 1 July 2021, to gain new insights and learn techniques from UK experts in obesity. By doing so you'll gain the skills needed to improve your clinical outcomes.


Case Discussions 1

ob0003cd1.1 | Case Discussions 1 | OU2021

Weight loss maintenance through a multidisciplinary healthy weight clinic in australia

Chen Juliana , Kaur Harpreet , Lord Reginald , Preda Veronica

Background: Multidisciplinary care is well recognised as being effective for weight and chronic disease management, and in weight loss maintenance. However, in the Australian context, there are inadequate obesity services. In recognising this health service gap, this led to the establishment of the privately funded university hospital-based weight management clinic – the ‘Healthy Weight Clinic’ to increase access to multidisciplinary services. The effec...

ob0003cd1.2 | Case Discussions 1 | OU2021

Liraglutide 3.0 mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials – The LIPOSAX first UK real-world evidence study

Dimitriadis Georgios K , Spencer Lewis , Dimitri Federica , Bate Danielle , Leca Bianca M , Duggirala Aparna , Davasgaium Allan , Aylwin Simon JB , Miras Alexander D , Vincent Royce P , le Roux Carel W , Christian Mark , Randeva Harpal S , Tripathi Gyanendra

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...